CagriSema vs Compounded Tirzepatide
A side-by-side research comparison of CagriSema and Compounded Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CagriSema | Compounded Tirzepatide |
|---|---|---|
| Full name | CagriSema (Cagrilintide + Semaglutide) | Compounded Tirzepatide (503B Pharmacy) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Compounded medication |
| Mechanism | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. | Dual agonist of both GLP-1 and GIP receptors. GLP-1 activation suppresses appetite and slows gastric emptying. GIP activation enhances fat metabolism, improves insulin sensitivity, and may protect against muscle loss. |
| Molecular weight | Combination product | 4813.45 Da |
| Half-life | 7 days (both components) | ~5 days |
| Bioavailability | High (SubQ) | ~80% subcutaneous |
| Typical dose | Cagrilintide 2.4mg + Semaglutide 2.4mg | 2.5-15 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous | Subcutaneous injection |
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Compounded Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Dual incretin pathway activation
- Better muscle preservation
- Improved A1c
- Cardiovascular protection
- Reduced insulin resistance
Related comparisons
Research and educational reference only. Not medical advice.